Aducanumab Setback? FDA Advisory Committee Meeting Presents Unexpected Snag
In an unexpected twist, the advisory committee that convened today on the experimental Alzheimer’s treatment aducanumab overwhelmingly said that drugmaker Biogen has failed to…